Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis
C infection, however most have been small, and reported rates have varied quite widely. …

Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is
highest in Egypt at >10% of the general population and China has the most people with HCV (…

Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists
of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify …

A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …

Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV)
infection are heterogeneous. We aimed to estimate stage‐specific fibrosis …

Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

To gain a clearer understanding of the rate of progression to cirrhosis and its determinants
in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic …

Despite notable scientific and medical advances, broader political, socioeconomic and
behavioural factors continue to undercut the response to the COVID-19 pandemic 1 , 2 . Here we …

Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and
telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained …